Armand Butera

Clinical and public health laboratories reported increased influenza virus detections over the past few weeks, but US cases remains comparatively low to previous flu seasons.

This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.